Sintbilo Tafolecimab Injection

1. Indications and Usage
Hypercholesterolemia: Used in combination with statins or other lipid-lowering therapies for adults with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) or mixed dyslipidemia.
Treatment Goal: To lower LDL-C, total cholesterol (TC), and apolipoprotein B (ApoB) levels in patients who have not achieved their LDL-C goals with moderate or high-dose statin therapy.
2. Dosage and Administration
Route of Administration: Subcutaneous injection ONLY (typically using a pre-filled auto-injector in the abdomen).
Recommended Dosage: 150 mg every 2 weeks; OR 450 mg every 4 weeks; OR 600 mg every 6 weeks.
Critical Administration Instructions:
Injection Site: Rotate injection sites. Do not inject into areas with active skin lesions, sunburn, or infection.
Preparation: Allow the auto-injector to reach room temperature (at least 30 minutes) before use. Visually inspect for particulates or discoloration; do not use if abnormal.
Missed Dose: Administer as soon as possible, then resume the regular schedule.
3. Mechanism of Action
PCSK9 Inhibition: Tafolecimab binds to circulating PCSK9, preventing it from interacting with hepatic LDL receptors.
LDL Receptor Recycling: By blocking PCSK9, it prevents the degradation of LDL receptors, leading to increased receptor density on the liver cell surface and enhanced clearance of LDL-C from the bloodstream.
4. Safety and Warnings
Hypersensitivity: Serious allergic reactions (e.g., rash, urticaria, angioedema) have been reported. Discontinue immediately if signs of anaphylaxis or hypersensitivity occur.
Hepatic Enzyme Elevation: Elevated liver enzymes have been observed; liver function should be monitored, particularly in patients with existing liver disease.
Pregnancy and Lactation: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Injection site reactions, upper respiratory tract infection, nasopharyngitis, arthralgia, back pain, diarrhea, and myalgia.
Clinical Research Highlights: Phase III clinical trials (e.g., CREDIT-1) demonstrated significant reductions in LDL-C levels in patients with primary hypercholesterolemia and mixed dyslipidemia when added to their existing statin regimens.
6. Drug Interactions
Statins and Ezetimibe: Population pharmacokinetic analyses suggest that statins and ezetimibe do not significantly affect the pharmacokinetics of tafolecimab.
Other Lipid-Lowering Agents: No formal drug-drug interaction studies have been conducted, but tafolecimab is intended to be used in combination with these agents.
Metabolism: As a monoclonal antibody, it is not expected to interact with cytochrome P450 enzymes or transporters.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Tafolecimab. Excipients: Histidine, arginine, sorbitol, polysorbate 80, and water for injection.
Appearance: Clear to slightly milky, colorless to pale yellow liquid.
Packaging: 150 mg/1 mL pre-filled auto-injector.
Storage: Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light.